VACINA DE PREFUSÃO DE PROTEÍNA F DO VÍRUS SINCICIAL RESPIRATÓRIO ADJUVANTADA (RSVPREF3OA) É IMUNOGÊNICA E BEM TOLERADA EM ADULTOS 50-59 ANOS, INCLUINDO ADULTOS COM RISCO AUMENTADO DE DOENÇA POR VSR
Lessandra Michelin (representando Murdo Ferguson)a,1, Tino F. Schwarzb, Sebastián A. Núñezc, Juan Rodríguez-Garcíad, Marek Mitale, Carlos Zalaf, Bernhard Schmittg, Nicole Toursarkissianh, Dolores Ochoa Mazarroi, Josef Großkopfj, Christine Voors-Pettek, Hemalini Mehtal, Hiwot Amare Hailemariamm, Magali de Heuschm, Silvia Damasom, Marie-Pierre Davidm, Dominique Descampsm, Judith Hillm, Corinne Vandermeulenm, Veronica Hulstrøm (representando o grupo de estudo RSV AO=ADJ-018 study group)m
a GSK, Rio de Janeiro, RJ, Brasil
1 Colchester Research Group, Truro, Canadá
b Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Alemanha
c Centro Medico Maffei, Buenos Aires, Argentina
d Preventive Medicine Service, Immunocompromised Patient Vaccination Unit, Son Espases University Hospital, Mallorca, Balearic Islands, Espanha
e Clinical Agniszka Mital Centrum Badan Klinic, Elblag, Polônia
f Vacunar, Sede Las Caňitas, Caba, Argentina
g Studienzentrum Mainz Mitte, Mainz, Alemanha
h Praxis Dr.Med. Nicole Toursarkissian, Berlin, Alemanha
i Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), Madrid, Espanha
j Praxis Dr.Med. Josef Großkopf, Wallerfing, Alemanha
k QPS Netherlands B.V., Groningen, Holanda
l Clinical Research Institute, Minneapolis, MN, EUA
m GSK, Wavre, Bélgica
Ver másRead
542
Timeswas read the article
252
Total PDF
290
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 7 | 1 | 8 |
| 2025 5 | 68 | 51 | 119 |
| 2025 4 | 52 | 31 | 83 |
| 2025 3 | 44 | 33 | 77 |
| 2025 2 | 40 | 23 | 63 |
| 2025 1 | 31 | 42 | 73 |
| 2024 12 | 28 | 39 | 67 |
| 2024 11 | 20 | 32 | 52 |
